Fig. 2
From: A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis
BI2536 accelerated the body weight loss and increased the mortality of bleomycin-treated mice. (A) C57BL/6 mice received bleomycin (3 mg/kg, intratracheal instillation) on day 0. BI2536 (injected intraperitoneally at a dose of 5, 10 or 20 mg/kg) or vehicle was administered twice a week. Analyses were performed on day 21. The change in the body weight of each group (B) and a Kaplan-Meier plot showing the survival in each group (C) (n = 3, control group; n = 7, bleomycin-alone group; n = 7, bleomycin + BI2536 5 mg/kg group; n = 7, bleomycin + BI2536 10 mg/kg group; n = 7, bleomycin + BI2536 20 mg/kg group). The results of body weight on each day in the bleomycin + BI2536 5, 10 and 20 mg/kg group were analyzed using a one-way analysis of variance followed by Dunnett’s multiple comparison test. * P = 0.01–0.05; ** P = 0.001–0.01, which are versus the value in the group treated with bleomycin only